Monday, August 15, 2022
Axcella Therapeutics (AXLA)
2Q Included The First of Two Phase 2 Data Announcements
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to restore cellular homeostasis in multiple key biological pathways and improve cellular energetic efficiency. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and non-alcoholic steatohepatitis (NASH), and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.
Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
2Q Included Long COVID-19 Data Announcement and An Increase In Cash. Axeclla reported a loss of $21.3 million or $(0.40) per share, compared with our estimate of $19.4 million or $(0.47) per share. During the quarter, the company raised about $25 million through a direct stock offering, bringing cash and marketable securities to $44.4 million as of June 30. The highlight of the quarter, in our opinion, was the announcement of Phase 2a data in Long COVID-19.
Phase 2a Data Was Encouraging. The company recently announced positive data from its Phase 2a trial testing AXA1125 in Long COVID-19. These data showed statistically significant improvements in several measures of physical and mental fatigue. The company reiterated plans to meet with the FDA to discuss the design of the next clinical test during the coming months….
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
